Ignite Creation Date:
2024-05-06 @ 8:25 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06376084
Status:
RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-17
Brief Title:
Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Carcinoma Non-Small-Cell Lung |
| Lung Neoplasms |
| Respiratory Tract Neoplasms |
| Thoracic Neoplasms |
| Neoplasms by Site |
| Neoplasms |
| Lung Diseases |
| Respiratory Tract Diseases |
| Carcinoma Bronchogenic |
| Bronchial Neoplasms |